Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Operating activities      
Net loss $ (13,149)   $ (121,290)
Adjustments to reconcile net loss used in operating activities:      
Depreciation and amortization 135   34
Stock-based compensation 3,241   629
Acquired in-process research and development 0   27,538
Excess of initial warrant fair value over private placement proceeds 0   79,276
Transaction costs paid pursuant to private placement 0   7,013
Transaction costs payable upon exercise of warrants issued in private placement 0   1,734
Cash payable to tax authorities related to withholding shares to satisfy RSU withholding obligations (509)  
Change in fair value of derivative liability (380)   120
Deferred taxes 8   7
Changes in assets and liabilities:      
Prepaid expenses and other assets 2,492   (53)
Lease incentive 0   158
Accounts payable 398   470
Accrued expenses and other liabilities (1,700)   (1,652)
Lease liability, net 7   (186)
Net cash used in operating activities (9,457)   (6,202)
Investing activities      
Cash assumed from AlmataBio Transaction 0   356
Net cash provided by investing activities 0   356
Financing activities      
Proceeds from Notes and warrants, net of debt issuance costs paid 0   0
Proceeds from private placement investment, gross 0   115,625
Transaction costs paid pursuant to private placement 0   (7,013)
Net cash provided by financing activities 0   108,612
(Decrease) increase in cash, cash equivalents and restricted cash (9,457)   102,766
Cash, cash equivalents, and restricted cash at beginning of period 134,696   7,546
Cash, cash equivalents, and restricted cash at end of period 125,239 $ 134,696 110,312
Supplemental disclosures of non-cash activities      
Cash payable to tax authorities related to withholding shares to satisfy RSU withholding obligations (509)   0
Issuance of common stock and Series C Preferred Stock pursuant to AlmataBio Transaction 0   12,272
Cash and cash equivalents 125,046 134,546 110,177
Restricted cash, current 62 19 4
Restricted cash, non-current 131 131 131
Total cash, cash equivalents and restricted cash $ 125,239 $ 134,696 $ 110,312